Description du projet
Remédier aux disparités parmi les essais cliniques en Afrique
L’Afrique, bien qu’elle supporte plus de 25 % du fardeau mondial des maladies en raison de divers facteurs tels que le manque d’expertise, le manque de clarté des réglementations et l’insuffisance des données, ne réalise actuellement que 3 % d’essais cliniques. Pour remédier à cette disparité, le projet CTCAN financé par l’UE va déployer le réseau CTCAN (Clinical Trials Community Africa Network). Il a pour but de favoriser la collaboration entre les principaux acteurs de la recherche clinique, les partenaires pharmaceutiques et d’autres homologues internationaux au sein de la région africaine. L’objectif principal du projet est d’améliorer la coordination et la viabilité de la recherche clinique par l’alignement des réseaux, la sensibilisation aux installations disponibles, la rationalisation des processus réglementaires et la promotion du partage des connaissances entre les régions. CTCAN est une précieuse plateforme qui regroupe les informations nécessaires pour renforcer la préparation à la pandémie et soutenir les efforts de recherche clinique.
Objectif
With over 25% of the global disease burden, only 3% of global clinical trials occur in Africa. This disproportion is driven by inadequacies in clinical research capacity, regulatory process ambiguity, deficient regional patient and disease area data, and lack of visibility of existing clinical research capabilities in Africa. To address this disproportion, this proposal seeks to establish the Clinical Trials Community Africa Network (CTCAN), a collaborative framework of key clinical research stakeholders in the African region, pharma partners, and other relevant international stakeholders, with the overarching goal of bringing more clinical trials to the region in a sustainable and coordinated manner. This collaboration will map and draw on the experience and expertise of already existing networks and initiatives. It will create a network of subnetworks that will foster coordination in clinical research, by ensuring and encouraging alignment in disease area prioritization, raising awareness and visibility of existing capacity from sites and labs across Africa, operationalising the regulatory processes across the region, and strengthen less experienced sites and labs through a clinical trial preparedness framework, while encouraging inter- and cross-continental knowledge and expertise sharing. CTCAN will use and expand the Clinical Trials Community (CTC) platform, an electronic platform consolidating data on researchers, regulations, sites, and epidemiology across the continent. The result will be an ever-present and ready-to-go pool of clinical research sites and labs with the agility to rapidly address new and emerging global health threats, epidemics, and pandemics, thereby efficiently contributing towards clinical research in pandemic preparedness. CTCAN will lay the foundation for a sustainable network of clinical trial sites and laboratories in sub-Saharan Africa by leveraging and initiating collaboration between existing sub-networks, funders, and pharma.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.2.1 - Health Main Programme
Régime de financement
HORIZON-JU-CSA - HORIZON JU Coordination and Support ActionsCoordinateur
2007 JOHANNESBURG
Afrique du Sud